Identification and Characterization of CYP2D6*56B, an Allele Associated with the Poor Metabolizer Phenotype

Autor: J D Eklund, Michael S. Phillips, JS Leeder, Robin E. Pearce, Mary Jayne Kennedy, Andrea Gaedigk, S W Alander, L.D. Bradford

Publikováno v: Clinical Pharmacology & Therapeutics. 81:817-820

A 5-year-old African-American girl presented with a CYP2D6*4xN/*10 genotype that was discordant with her poor metabolizer phenotype determined with the probe drug dextromethorphan. Both phenotype and genotype were confirmed in repeat assessments, sug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1e9063934de66c43221a4f61159e82e
https://doi.org/10.1038/sj.clpt.6100125

Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals

Autor: M A Smith, R Ghannadan, JS Leeder, C J D Ross, Phillips, Bruce Carleton, Robert L. Poole, Hayden

Publikováno v: Pharmacoepidemiology and drug safety. 18(8)

Purpose Adverse drug reactions (ADRs) rank as the fifth leading cause of death in the western world. The nature and scope of these ADRs in children are not predictable based on post market surveillance reports that rely heavily on adult drug experien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9101ff0bde1546ace0c31fc75c1c46b
https://pubmed.ncbi.nlm.nih.gov/19507171

Genetic Variants in Lung Development Genes and the Pathogenesis of Impaired Lung Function in Obstructive Airways Diseases

Autor: S Sharma, B Raby, K Tantisira, D Demeo, V Carey, A Murphy, J Celedon, A Rogers, J Torday, D Warburton, JS Leeder, E Silverman

Publikováno v: B26. PULMONARY DEVELOPMENTAL BIOLOGY.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6c700dbef17b7f39a89cce97d397c5e3
https://doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2630

Application of pharmacogenomic strategies to the study of drug-induced birth defects

Autor: JS Leeder, Allen A. Mitchell

Publikováno v: Clinical pharmacology and therapeutics. 81(4)

Approximately 3% of all infants are born with one or more major birth defects, resulting in >150,000 affected babies each year in the US alone.1 At present, birth defects account for more than 21% of all infant deaths, making them the leading cause o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a0e29c07406b1bbb14e28afdbaa64f
https://pubmed.ncbi.nlm.nih.gov/17314924

Age-Dependent Abundance of CYP450 Enzymes Involved in Metronidazole Metabolism: Application to Pediatric PBPK Modeling.

Autor: Parvez MM; Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA., Thakur A; Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA., Mehrotra A; Department of Pharmaceutics, University of Washington, Seattle, Washington, USA., Stancil S; Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy-Kansas City, Kansas City, Missouri, USA.; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA., Pearce RE; Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy-Kansas City, Kansas City, Missouri, USA.; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA., Basit A; Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA., Leeder JS; Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy-Kansas City, Kansas City, Missouri, USA.; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA., Prasad B; Department of Pharmaceutical Sciences, Washington State University, Spokane, Washington, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Oct; Vol. 116 (4), pp. 1090-1099. Date of Electronic Publication: 2024 Jul 02.